AGENUS INC
AGEN · XNASCIK 1098972fmd_11F3241RW02FY7Q3EESEMFDWCVManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 23 | 43 | 37 | 150 | – | 296 | 98 | 156 | 103 | 114 |
| Cost of revenue | – | – | – | – | 2 | 3 | 11 | 3 | 0 | 1 |
| Gross profit | – | – | – | – | – | 292 | 87 | 153 | 103 | 113 |
| Provision for credit losses | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Research and development | 95 | 116 | 125 | 168 | 143 | 179 | 187 | 235 | 156 | 79 |
| Compensation and benefits | – | – | – | – | – | – | 70 | 76 | 62 | 40 |
| Operating income | (107) | (104) | (124) | (70) | (117) | 26 | (179) | (160) | (120) | (20) |
| Interest expense | 19 | 31 | – | – | – | – | 64 | 104 | 120 | 56 |
| Interest and investment income | – | – | – | – | – | – | 2 | 6 | 3 | 0 |
| Other non-operating income (expense) | (2) | 2 | (2) | 0 | (2) | 5 | 13 | 0 | 6 | (2) |
| Income before taxes | (127) | (121) | – | – | – | – | – | (257) | (232) | (3) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (127) | (121) | – | – | – | – | – | (257) | (232) | (3) |
| Net income | (127) | (121) | (162) | (112) | (183) | (29) | (231) | (257) | (232) | (3) |
| Net income to common shareholders | (127) | (121) | (160) | (108) | (181) | (24) | (220) | (246) | (227) | (0) |